CoChat
Sign Up
Cited by 25

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Review of flow cytometry as a tool for cell and gene therapy

Lazarski, Christopher A., Hanley, Patrick J.·2024·Cytotherapy
DOI 10.1016/j.jcyt.2023.10.005
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jcyt.2023.10.005

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Show all 5 references

Research works printed but not linked: 97

  1. Jaye, 2012, Translational applications of flow cytometry in clinical practice, J Immunol, 188, 4715, 10.4049/jimmunol.1290017 · DOI
  2. Cory, 1987, Detection of human immunodeficiency virus-infected lymphoid cells at low frequency by flow cytometry, Journal of immunological methods, 105, 71, 10.1016/0022-1759(87)90415-7 · DOI
  3. Fischl, 1987, The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial, The New England journal of medicine, 317, 185, 10.1056/NEJM198707233170401 · DOI · Paper page
  4. Barlogie, 1980, Characterization of hematologic malignancies by flow cytometry, Blood Cells, 6, 719
  5. Civin, 1984, Antigenic analysis of hematopoiesis. III. A hematopoietic progenitor cell surface antigen defined by a monoclonal antibody raised against KG-1a cells, J Immunol, 133, 157, 10.4049/jimmunol.133.1.157 · DOI
  6. Sutherland, 1996, The ISHAGE guidelines for CD34+ cell determination by flow cytometry. International Society of Hematotherapy and Graft Engineering, J Hematother, 5, 213, 10.1089/scd.1.1996.5.213 · DOI
  7. Herzenberg, 2002, The history and future of the fluorescence activated cell sorter and flow cytometry: a view from Stanford, Clin Chem, 48, 1819, 10.1093/clinchem/48.10.1819 · DOI
  8. McKinnon, 2018, Flow cytometry: an overview, Curr Protoc Immunol, 120, 5.1.1, 10.1002/cpim.40 · DOI · Paper page
  9. Dunphy, 2004, Applications of flow cytometry and immunohistochemistry to diagnostic hematopathology, Arch Pathol Lab Med, 128, 1004, 10.5858/2004-128-1004-AOFCAI · DOI
  10. De Rosa, 2001, 11-color, 13-parameter flow cytometry: identification of human naive T cells by phenotype, function, and T-cell receptor diversity, Nature medicine, 7, 245, 10.1038/84701 · DOI
  11. Perez, 2002, Simultaneous measurement of multiple active kinase states using polychromatic flow cytometry, Nature biotechnology, 20, 155, 10.1038/nbt0202-155 · DOI
  12. Demaret, 2021, Monitoring CAR T-cells using flow cytometry, Cytometry B Clin Cytom, 100, 218, 10.1002/cyto.b.21941 · DOI
  13. Lamoreaux, 2006, Intracellular cytokine optimization and standard operating procedure, Nat Protoc, 1, 1507, 10.1038/nprot.2006.268 · DOI · Paper page
  14. Lovelace, 2011, Multiparameter intracellular cytokine staining, Methods Mol Biol, 699, 165, 10.1007/978-1-61737-950-5_8 · DOI
  15. Krutzik, 2011, Phospho flow cytometry methods for the analysis of kinase signaling in cell lines and primary human blood samples, Methods Mol Biol, 699, 179, 10.1007/978-1-61737-950-5_9 · DOI
  16. Kim, 2015, Assaying cell cycle status using flow cytometry, Curr Protoc Mol Biol, 111, 10.1002/0471142727.mb2806s111 · DOI
  17. Tario, 2011, Tracking immune cell proliferation and cytotoxic potential using flow cytometry, Methods Mol Biol, 699, 119, 10.1007/978-1-61737-950-5_7 · DOI
  18. Hoppner, 2002, A flow-cytometry based cytotoxicity assay using stained effector cells in combination with native target cells, Journal of immunological methods, 267, 157, 10.1016/S0022-1759(02)00167-9 · DOI
  19. Venken, 2007, A CFSE based assay for measuring CD4+CD25+ regulatory T cell mediated suppression of auto-antigen specific and polyclonal T cell responses, Journal of immunological methods, 322, 1, 10.1016/j.jim.2007.01.025 · DOI
  20. Riccardi, 2006, Analysis of apoptosis by propidium iodide staining and flow cytometry, Nat Protoc, 1, 1458, 10.1038/nprot.2006.238 · DOI · Paper page
  21. Ferrer-Font, 2020, Panel design and optimization for high-dimensional immunophenotyping assays using spectral flow cytometry, Curr Protoc Cytom, 92, e70, 10.1002/cpcy.70 · DOI
  22. Lin, 2018, Mass cytometry assays for antigen-specific T cells using CyTOF, Methods Mol Biol, 1678, 37, 10.1007/978-1-4939-7346-0_3 · DOI
  23. Davies, 2016, An optimized multiplex flow cytometry protocol for the analysis of intracellular signaling in peripheral blood mononuclear cells, Journal of immunological methods, 436, 58, 10.1016/j.jim.2016.06.007 · DOI
  24. Blouin, 2021, A practical guide to chimerism analysis: review of the literature and testing practices worldwide, Hum Immunol, 82, 838, 10.1016/j.humimm.2021.07.013 · DOI
  25. De Rosa, 2003, Beyond six colors: a new era in flow cytometry, Nature medicine, 9, 112, 10.1038/nm0103-112 · DOI
  26. Nolan, 2013, Spectral flow cytometry, Curr Protoc Cytom Chapter, 1
  27. Hont, 2019, Immunotherapy of relapsed and refractory solid tumors with ex vivo expanded multi-tumor associated antigen specific cytotoxic T lymphocytes: a phase I study, J Clin Oncol, 37, 2349, 10.1200/JCO.19.00177 · DOI
  28. Dave, 2022, Tumor-associated antigen-specific T cells with nivolumab are safe and persist in vivo in relapsed/refractory Hodgkin lymphoma, Blood Adv, 6, 473, 10.1182/bloodadvances.2021005343 · DOI
  29. Kinoshita, 2022, Outcome of donor-derived TAA-T cell therapy in patients with high-risk or relapsed acute leukemia post allogeneic BMT, Blood Adv, 6, 2520, 10.1182/bloodadvances.2021006831 · DOI
  30. Tanna, 2019, Critical testing and parameters for consideration when manufacturing and evaluating tumor-associated antigen-specific T cells, Cytotherapy, 21, 278, 10.1016/j.jcyt.2019.02.004 · DOI
  31. Lazarski, 2021, Identification of new cytokine combinations for antigen-specific T-cell therapy products via a high-throughput multi-parameter assay, Cytotherapy, 23, 65, 10.1016/j.jcyt.2020.08.006 · DOI
  32. Lyons, 2000, Analysing cell division in vivo and in vitro using flow cytometric measurement of CFSE dye dilution, Journal of immunological methods, 243, 147, 10.1016/S0022-1759(00)00231-3 · DOI
  33. Lyons, 2013, Flow cytometric analysis of cell division by dilution of CFSE and related dyes, Curr Protoc Cytom Chapter, 9
  34. Wallace, 2008, Tracking antigen-driven responses by flow cytometry: monitoring proliferation by dye dilution, Cytometry A, 73, 1019, 10.1002/cyto.a.20619 · DOI
  35. Pitsillides, 2011, Cell labeling approaches for fluorescence-based in vivo flow cytometry, Cytometry A, 79, 758, 10.1002/cyto.a.21125 · DOI
  36. Dawson, 1990, Comparative assessment of proliferation and DNA content in breast carcinoma by image analysis and flow cytometry, The American journal of pathology, 136, 1115
  37. Darzynkiewicz, 2001, Flow cytometry in analysis of cell cycle and apoptosis, Seminars in hematology, 38, 179, 10.1016/S0037-1963(01)90051-4 · DOI
  38. Darzynkiewicz, 2001, Determining cell cycle stages by flow cytometry, Curr Protoc Cell Biol Chapter, 8
  39. Estevam, 2011, Validation of a flow cytometry based G(2)M delay cell cycle assay for use in evaluating the pharmacodynamic response to Aurora A inhibition, Journal of immunological methods, 363, 135, 10.1016/j.jim.2010.09.021 · DOI
  40. Roederer, 2011, Interpretation of cellular proliferation data: avoid the panglossian, Cytometry A, 79, 95, 10.1002/cyto.a.21010 · DOI
  41. Dunkley, 1974, A modified 51Cr release assay for cytotoxic lymphocytes, Journal of immunological methods, 6, 39, 10.1016/0022-1759(74)90088-X · DOI
  42. Miller, 1974, Quantitative analysis of the 51Cr release cytotoxicity assay for cytotoxic lymphocytes, Cellular immunology, 14, 284, 10.1016/0008-8749(74)90212-3 · DOI
  43. Bach, 1966, One-way stimulation in mixed leukocyte cultures, Science, 153, 545, 10.1126/science.153.3735.545 · DOI
  44. Lazarski, 2021, Flow-based analysis of cell division identifies highly active populations within plasma products during mixed lymphocyte cultures, Blood Transfus, 19, 456
  45. Michalek, 2003, Identification and monitoring of graft-versus-host specific T-cell clone in stem cell transplantation, Lancet, 361, 1183, 10.1016/S0140-6736(03)12917-0 · DOI
  46. Scheinberg, 2006, Alloreactive T cell clonotype recruitment in a mixed lymphocyte reaction: implications for graft engineering, Experimental hematology, 34, 788, 10.1016/j.exphem.2006.03.001 · DOI
  47. Zarcone, 1986, Flow cytometry evaluation of cell-mediated cytotoxicity, Journal of immunological methods, 94, 247, 10.1016/0022-1759(86)90239-5 · DOI
  48. Lecoeur, 2001, A novel flow cytometric assay for quantitation and multiparametric characterization of cell-mediated cytotoxicity, Journal of immunological methods, 253, 177, 10.1016/S0022-1759(01)00359-3 · DOI
  49. Kim, 2007, A novel multiparametric flow cytometry-based cytotoxicity assay simultaneously immunophenotypes effector cells: comparisons to a 4 h 51Cr-release assay, Journal of immunological methods, 325, 51, 10.1016/j.jim.2007.05.013 · DOI
  50. Wagner, 2019, Characterization of human natural killer cells for therapeutic use, Cytotherapy, 21, 315, 10.1016/j.jcyt.2018.11.001 · DOI
  51. Godoy-Ramirez, 2005, A novel assay for assessment of HIV-specific cytotoxicity by multiparameter flow cytometry, Cytometry A, 68, 71, 10.1002/cyto.a.20189 · DOI
  52. Yin, 2015, Detection of Intracellular cytokines by flow cytometry, Curr Protoc Immunol, 110, 6.24.1, 10.1002/0471142735.im0624s110 · DOI
  53. Jaimes, 2011, Quality assurance of intracellular cytokine staining assays: analysis of multiple rounds of proficiency testing, Journal of immunological methods, 363, 143, 10.1016/j.jim.2010.08.004 · DOI
  54. Keller, 2020, SARS-CoV-2-specific T cells are rapidly expanded for therapeutic use and target conserved regions of the membrane protein, Blood, 136, 2905, 10.1182/blood.2020008488 · DOI
  55. Manz, 1995, Analysis and sorting of live cells according to secreted molecules, relocated to a cell-surface affinity matrix, Proceedings of the National Academy of Sciences of the United States of America, 92, 1921, 10.1073/pnas.92.6.1921 · DOI
  56. Fujiki, 2008, Quantification of green fluorescent protein by in vivo imaging, PCR, and flow cytometry: comparison of transgenic strains and relevance for fetal cell microchimerism, Cytometry A, 73, 11, 10.1002/cyto.a.20533 · DOI
  57. Freen-van Heeren, 2021, Addressing HIV-1 latency with Flow-FISH: Finding, characterizing and targeting HIV-1 infected cells, Cytometry A, 99, 861, 10.1002/cyto.a.24462 · DOI
  58. Krutzik, 2011, Fluorescent cell barcoding for multiplex flow cytometry, Curr Protoc Cytom Chapter, 6, 6.31.1
  59. Krutzik, 2006, Fluorescent cell barcoding in flow cytometry allows high-throughput drug screening and signaling profiling, Nat Methods, 3, 361, 10.1038/nmeth872 · DOI
  60. Vignali, 2000, Multiplexed particle-based flow cytometric assays, Journal of immunological methods, 243, 243, 10.1016/S0022-1759(00)00238-6 · DOI
  61. Chowdhury, 2009, Validation and comparison of two multiplex technologies, Luminex and Mesoscale Discovery, for human cytokine profiling, Journal of immunological methods, 340, 55, 10.1016/j.jim.2008.10.002 · DOI
  62. Curpan, 2011, High-throughput screen for the chemical inhibitors of antiapoptotic bcl-2 family proteins by multiplex flow cytometry, Assay Drug Dev Technol, 9, 465, 10.1089/adt.2010.0363 · DOI
  63. Wu, 2013, Single cell microRNA analysis using microfluidic flow cytometry, PloS one, 8, e55044, 10.1371/journal.pone.0055044 · DOI
  64. Lee, 2007, High-throughput, sensitive, and accurate multiplex PCR-microsphere flow cytometry system for large-scale comprehensive detection of respiratory viruses, J Clin Microbiol, 45, 2626, 10.1128/JCM.02501-06 · DOI
  65. Bandura, 2009, Mass cytometry: technique for real time single cell multitarget immunoassay based on inductively coupled plasma time-of-flight mass spectrometry, Anal Chem, 81, 6813, 10.1021/ac901049w · DOI · Paper page
  66. Iyer, 2022, CyTOF((R)) for the Masses, Frontiers in immunology, 13, 10.3389/fimmu.2022.815828 · DOI
  67. Bendall, 2011, Single-cell mass cytometry of differential immune and drug responses across a human hematopoietic continuum, Science, 332, 687, 10.1126/science.1198704 · DOI · Paper page
  68. Abdelaal, 2019, CyTOFmerge: integrating mass cytometry data across multiple panels, Bioinformatics, 35, 4063, 10.1093/bioinformatics/btz180 · DOI
  69. Ferrer-Font, 2021, Panel optimization for high-dimensional immunophenotyping assays using full-spectrum flow cytometry, Curr Protoc, 1, e222, 10.1002/cpz1.222 · DOI
  70. Sahir, 2020, Development of a 43 color panel for the characterization of conventional and unconventional T-cell subsets, B cells, NK cells, monocytes, dendritic cells, and innate lymphoid cells using spectral flow cytometry, Cytometry A
  71. Park, 2020, OMIP-069: forty-color full spectrum flow cytometry panel for deep immunophenotyping of major cell subsets in human peripheral blood, Cytometry A, 97, 1044, 10.1002/cyto.a.24213 · DOI · Paper page
  72. Morales-Kastresana, 2017, Flow cytometric analysis of extracellular vesicles, Methods Mol Biol, 1545, 215, 10.1007/978-1-4939-6728-5_16 · DOI
  73. Edwards, 2004, Flow cytometry for high-throughput, high-content screening, Curr Opin Chem Biol, 8, 392, 10.1016/j.cbpa.2004.06.007 · DOI
  74. Edwards, 2007, High-throughput flow cytometry for drug discovery, Expert Opin Drug Discov, 2, 685, 10.1517/17460441.2.5.685 · DOI
  75. Sklar, 2007, Flow cytometry for drug discovery, receptor pharmacology and high-throughput screening, Current opinion in pharmacology, 7, 527, 10.1016/j.coph.2007.06.006 · DOI
  76. Bhagwat, 2018, An integrated flow cytometry-based platform for isolation and molecular characterization of circulating tumor single cells and clusters, Scientific reports, 8, 5035, 10.1038/s41598-018-23217-5 · DOI · Paper page
  77. Owens, 2000, Validation and quality control of immunophenotyping in clinical flow cytometry, Journal of immunological methods, 243, 33, 10.1016/S0022-1759(00)00226-X · DOI
  78. Hulspas, 2010, Titration of fluorochrome-conjugated antibodies for labeling cell surface markers on live cells, Curr Protoc Cytom Chapter, 6
  79. Hulspas, 2009, Considerations for the control of background fluorescence in clinical flow cytometry, Cytometry B Clin Cytom, 76, 355, 10.1002/cyto.b.20485 · DOI · Paper page
  80. Erez, 2018, Modeling of cytometry data in logarithmic space: when is a bimodal distribution not bimodal?, Cytometry A, 93, 611, 10.1002/cyto.a.23333 · DOI
  81. Roederer, 2001, Spectral compensation for flow cytometry: visualization artifacts, limitations, and caveats, Cytometry, 45, 194, 10.1002/1097-0320(20011101)45:3<194::AID-CYTO1163>3.0.CO;2-C · DOI
  82. Green, 2011, Recommendations for the validation of flow cytometric testing during drug development: I instrumentation, Journal of immunological methods, 363, 104, 10.1016/j.jim.2010.07.004 · DOI
  83. Saeys, 2016, Computational flow cytometry: helping to make sense of high-dimensional immunology data, Nature reviews. Immunology, 16, 449, 10.1038/nri.2016.56 · DOI
  84. den Braanker, 2021, How to prepare spectral flow cytometry datasets for high dimensional data analysis: a practical workflow, Frontiers in immunology, 12, 10.3389/fimmu.2021.768113 · DOI
  85. O'Hara, 2011, Recommendations for the validation of flow cytometric testing during drug development: II assays, Journal of immunological methods, 363, 120, 10.1016/j.jim.2010.09.036 · DOI
  86. Clinical Laboratory Standards Institute. Guideline H62: Validation of Assays Performed by Flow Cytometry (CLSI, 2021). ©. Wiley Periodicals LLC; 2023 (Accessed October 31, 2023).
  87. Wang L, Perfetto S, Hoffman R, Elliott J, Lin-Gibson S, Bauer S, Degheidy H, Arcidiacono J, Virginia L. (2019). Workshop 13: Building Measurement Assurance in Flow Cytometry, Cytometry Part A, [online], https://tsapps.nist.gov/publication/get_pdf.cfm?pub_id=926340 (Accessed October 31, 2023).
  88. Mfarrej, 2021, Validation of a flow cytometry-based method to quantify viable lymphocyte subtypes in fresh and cryopreserved hematopoietic cellular products, Cytotherapy, 23, 77, 10.1016/j.jcyt.2020.06.005 · DOI
  89. Selliah, 2023, Flow cytometry method validation protocols, Curr Protoc, 3, e868, 10.1002/cpz1.868 · DOI
  90. Finak, 2016, Standardizing flow cytometry immunophenotyping analysis from the Human ImmunoPhenotyping Consortium, Scientific reports, 6, 20686, 10.1038/srep20686 · DOI
  91. Rosenblatt, 1997, Theoretical basis for sampling statistics useful for detecting and isolating rare cells using flow cytometry and cell sorting, Cytometry, 27, 233, 10.1002/(SICI)1097-0320(19970301)27:3<233::AID-CYTO4>3.0.CO;2-F · DOI
  92. Wang, 2017, Standardization, Calibration, and Control in Flow Cytometry, Curr Protoc Cytom, 79, 1.3.1
  93. Kalina, 2020, Reproducibility of Flow Cytometry Through Standardization: Opportunities and Challenges, Cytometry A, 97, 137, 10.1002/cyto.a.23901 · DOI
  94. Mizrahi, 2018, Quantitative flow cytometry: concerns and recommendations in clinic and research, Cytometry B Clin Cytom, 94, 211, 10.1002/cyto.b.21515 · DOI
  95. Berg Luecke, 2019, Reliable Protocols for flow cytometry analysis of intracellular proteins in pluripotent stem cell derivatives: a fit-for-purpose approach, Curr Protoc Stem Cell Biol, 50, e94, 10.1002/cpsc.94 · DOI
  96. Sarikonda, 2021, Monitoring CAR-T cell kinetics in clinical trials by multiparametric flow cytometry: benefits and challenges, Cytometry B Clin Cytom, 100, 72, 10.1002/cyto.b.21891 · DOI
  97. Davis, 2011, CLS entry level competencies in flow cytometry, Clin Lab Sci, 24, 29, 10.29074/ascls.24.1.29 · DOI

Cited by

Sorted by citations

See all 25

Metadata

Authors
Lazarski, C. A., & Hanley, P. J.
ORCID
Venue
Cytotherapy
Publisher
Elsevier BV
Published
2024-02
Volume
26
Issue
2
Pages
103-112
ISSN
1465-3249
DOI
10.1016/j.jcyt.2023.10.005
Cited by
25
References
5
Language
en
Licence
Funders
National Cancer Institute (2P01CA148600-07A1)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review